Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.

Kerr D. et al, (2019), Oncologist

Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage

GLAIRE M. et al, (2019), British Journal of Cancer

Association analyses identify 31 new risk loci for colorectal cancer susceptibility.

Law PJ. et al, (2019), Nat Commun, 10

Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.

Barrow P. et al, (2019), Histopathology

Oxford Textbook of Cancer Biology

Pezzella F. et al, (2019)

Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.

Jiang W. et al, (2019), Int J Cancer, 144, 2161 - 2168

An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.

Li N. et al, (2019), Oncogenesis, 8

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Eyre TA. et al, (2019), Cancer, 125, 99 - 108

Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers.

Nielsen B. et al, (2018), J Natl Cancer Inst, 110, 1400 - 1408

Donors, Noncommunicable Diseases, and Universal Health Coverage to High-quality Healthcare: An Opportunity for Action on Global Functions for Health.

Baines LS. and Kerr DJ., (2018), J Epidemiol Glob Health, 8

Prognostic markers for colorectal cancer.

Tyrrell HEJ. and Kerr D., (2018), Oncotarget, 9, 33060 - 33061

Facing the Global Challenges of Access to Cancer Medication.

Jazieh AR. et al, (2018), J Glob Oncol, 4, 1 - 7

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E. et al, (2018), Lancet Gastroenterol Hepatol, 3, 635 - 643

Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia.

Fan Y-F. et al, (2018), J Glob Oncol, 4, 1 - 4

Somatic Mutations of Beta2-Microglobulin are Correlated with a Lack of Disease Recurrence in a Subset of Stage II Mismatch Repair Deficient Colorectal Cancers from the QUASAR Trial

Richman SD. et al, (2018), JOURNAL OF PATHOLOGY, 246, S27 - S27

An evaluation of the clinical utility of a panel of variants in DPYD and ENOSF1 for predicting common capecitabine related toxicities

Palles C. et al, (2018), ANNALS OF ONCOLOGY, 29

The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.

Huijbers A. et al, (2018), J Surg Oncol, 117, 1043 - 1048

Cancer control in war-torn Iraq.

Alwan N. and Kerr D., (2018), Lancet Oncol, 19, 291 - 292

Chromatin organisation and cancer prognosis: a pan-cancer study.

Kleppe A. et al, (2018), Lancet Oncol, 19, 356 - 369

Prognostic markers for colorectal cancer: estimating ploidy and stroma.

Danielsen HE. et al, (2018), Ann Oncol, 29, 616 - 623

Load More

Include forthcoming?